Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Globe Newswire•03/11/2026•07:00 ET
0
Key Highlights
- ➤$1.0 billion cash, equivalents and securities supports operating plans into mid-2029
- ➤Risto-cel U.S. BLA submission expected as early as year-end 2026
- ➤BEAM-302 pivotal-cohort dosing completion expected in first half of 2027
- ➤BEAM-304 Phase 1/2 dosing expected to begin in early 2027
- ➤Third-quarter net loss widened to $134.4 million, or $1.28 per share
Expert Statements
John Evans, Chief executive officer of Beam Therapeutics
“Our progress this quarter reflects the growing maturity and momentum of Beam’s platform, with predictable clinical translation across four distinct programs and multiple potentially transformative medicines advancing toward patients, bringing our vision for a new era of genetic medicine increasingly within reach”
John Evans, Chief executive officer of Beam Therapeutics
“We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027. Recently, initial BEAM-301 clinical trial data showed exciting early evidence of clinical activity and provided further clinical validation of our in vivo LNP platform. Together with the planned initiation of BEAM-304 dosing in early 2027, these milestones reinforce our confidence in a platform designed to translate predictably, carry knowledge forward from one program to the next, and progressively expand the number of patients who can benefit from base editing.”
Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027
U.S. Biologics License Application (BLA) Submission for Risto-cel in Sickle Cell Disease Expected as Early as Year-End 2026
Get started
Create a free account to read the full story.